🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "huge turning point" in the effort against drug-resistant strains of the pathogen, according to researchers.

A Global Health Concern

Gonorrhoea infections are escalating around the world, with estimates suggesting more than 82 million new cases annually. Notably increased rates are observed in the African continent and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an important and timely step in the context of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Medical experts are deeply concerned about the increase in treatment-resistant strains. The WHO has listed it as a "priority pathogen". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Drugs Gain Clearance

Zoliflodacin, marketed under the name a brand name, was authorized by the American regulatory agency in December for use against gonorrhoea. This infection can lead to major issues, including infertility. Researchers believe that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in the same week. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This milestone signifies a major breakthrough in the therapy of highly resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

According to findings detailed in a major medical journal, the new drug eradicated the vast majority of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which involves two antibiotics. The trial involved over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the ability to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians treating patients have expressed optimism. Access to a single-dose, oral treatment of this kind is seen as a "game-changer" for gonorrhoea control. This is considered crucial to reduce the burden of the infection for people and to stop the proliferation of untreatable gonorrhoea around the world.